Movement Alert｜Regeneron Pharmaceuticals Rises 3.19% in Regular Trading, Q2 Earnings Massively Beat Expectations

Market Focus07-30

On July 30, Regeneron Pharmaceuticals rose 3.19% in regular trading, trading at $705.8/share, with turnover of $240 million. The rally was driven by the company's Q2 earnings report released pre-market, which significantly exceeded Wall Street expectations.

Regeneron reported Q2 adjusted earnings of $14.29 per diluted share, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% increase over $12.89 in the year-ago period. Revenue came in at $4.29 billion, well above the $3.82 billion expected and up from $3.68 billion a year earlier. Notably, the company had previously disclosed in an SEC filing that it expected Q2 GAAP and non-GAAP diluted EPS to decline by approximately $1, making the actual blowout results an even greater positive surprise for investors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124715386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124715386","market":"us","top_or_hot":-1,"title":"Movement Alert｜Regeneron Pharmaceuticals Rises 3.19% in Regular Trading, Q2 Earnings Massively Beat Expectations","media":"Market Focus","content":"<p><p>On July 30, Regeneron Pharmaceuticals rose 3.19% in regular trading, trading at $705.8/share, with turnover of $240 million. The rally was driven by the company's Q2 earnings report released pre-market, which significantly exceeded Wall Street expectations.</p><p>Regeneron reported Q2 adjusted earnings of $14.29 per diluted share, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% increase over $12.89 in the year-ago period. Revenue came in at $4.29 billion, well above the $3.82 billion expected and up from $3.68 billion a year earlier. Notably, the company had previously disclosed in an SEC filing that it expected Q2 GAAP and non-GAAP diluted EPS to decline by approximately $1, making the actual blowout results an even greater positive surprise for investors.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Regeneron Pharmaceuticals Rises 3.19% in Regular Trading, Q2 Earnings Massively Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Regeneron Pharmaceuticals Rises 3.19% in Regular Trading, Q2 Earnings Massively Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, Regeneron Pharmaceuticals rose 3.19% in regular trading, trading at $705.8/share, with turnover of $240 million. The rally was driven by the company's Q2 earnings report released pre-market, which significantly exceeded Wall Street expectations.</p><p>Regeneron reported Q2 adjusted earnings of $14.29 per diluted share, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% increase over $12.89 in the year-ago period. Revenue came in at $4.29 billion, well above the $3.82 billion expected and up from $3.68 billion a year earlier. Notably, the company had previously disclosed in an SEC filing that it expected Q2 GAAP and non-GAAP diluted EPS to decline by approximately $1, making the actual blowout results an even greater positive surprise for investors.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"","article_id":"1124715386","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124715386","pubTimestamp":1785423009,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Regeneron Pharmaceuticals rose 3.19% in regular trading, trading at $705.8/share, with turnover of $240 million. The rally was driven by the company's Q2 earnings report released...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"走势提醒|再生元制药常规交易上涨3.19%，第二季度盈利大幅超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1},"content_text":"On July 30, Regeneron Pharmaceuticals rose 3.19% in regular trading, trading at $705.8/share, with turnover of $240 million. The rally was driven by the company's Q2 earnings report released pre-market, which significantly exceeded Wall Street expectations.Regeneron reported Q2 adjusted earnings of $14.29 per diluted share, beating the analyst consensus estimate of $10.26 by 39.28% and representing a 10.86% increase over $12.89 in the year-ago period. Revenue came in at $4.29 billion, well above the $3.82 billion expected and up from $3.68 billion a year earlier. Notably, the company had previously disclosed in an SEC filing that it expected Q2 GAAP and non-GAAP diluted EPS to decline by approximately $1, making the actual blowout results an even greater positive surprise for investors.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124715386","isCrawlerRequest":true}